KalVista Pharmaceuticals Inc (KALV)

Name: KalVista Pharmaceuticals Inc Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-09-30

Latest Quarter

2025-09-30

Revenue

$13.7M

Net Income

-$49.5M

Operating Margin

-336.3%

Free Cash Flow

-$153M

Debt / Assets

62.0%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for KalVista Pharmaceuticals Inc (KALV).
Income Statement (Quarterly)	2025-09-30	2025-07-31	2025-01-31	2024-10-31
Revenue	13,692,000	1,426,000	0	0
Cost of Revenue	1,232,000	590,000	0	0
Gross Profit	12,460,000	836,000	0	0
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	46,517,000	44,683,000	30,346,000	29,201,000
Operating Expenses	58,510,000	59,845,000	42,940,000	45,811,000
Operating Income	-46,050,000	-59,009,000	-42,940,000	-45,811,000
Interest Expense	4,757,000	3,522,000	2,842,000	0
Income Before Tax	-47,325,000	-57,939,000	-44,262,000	-42,268,000
Income Tax Expense	2,157,000	2,157,000	4,247,000	0
Net Income	-49,482,000	-60,096,000	-48,509,000	-42,268,000
Per Share
EPS	-0.92	-1.12	-0.92	-0.91
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for KalVista Pharmaceuticals Inc (KALV).
Income Statement (Annual)	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30
Revenue	0	0	0	0	0
Cost of Revenue	0	86,167,000	802,000	743,000	0
Gross Profit	0	-86,167,000	-802,000	-743,000	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	116,286,000	54,278,000	30,595,000	26,446,000	16,637,000
Operating Expenses	187,995,000	54,278,000	110,871,000	96,613,000	57,923,000
Operating Income	-187,995,000	-140,445,000	-110,871,000	-96,613,000	-57,923,000
Interest Expense	5,785,000	0	0	1,090,000	0
Income Before Tax	-180,052,000	-135,096,000	-92,907,000	-82,339,000	-46,244,000
Income Tax Expense	3,392,000	-8,452,000	-18,054,000	-13,827,000	0
Net Income	-183,444,000	-126,644,000	-74,853,000	-68,512,000	-46,244,000
Per Share
EPS	-3.69	-3.44	-2.68	-2.80	-2.42
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for KalVista Pharmaceuticals Inc (KALV).
Balance Sheet (Quarterly)	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Assets
Cash and Cash Equivalents	98,644,000	31,789,000	56,238,000	30,732,000
Short Term Investments	89,002,000	178,612,000	93,137,000	135,470,000
Net Receivables	15,141,000	10,871,000	16,568,000	14,098,000
Inventory	0	0	0	2,709,000
Total Current Assets	241,690,000	225,690,000	172,326,000	193,647,000
Property Plant Equipment	1,988,000	9,147,000	10,770,000	10,040,000
Goodwill and Intangibles	0	0	0	0
Total Assets	250,770,000	235,404,000	183,202,000	203,880,000
Liabilities
Account Payables	4,883,000	9,107,000	4,817,000	3,638,000
Short Term Debt	1,977,000	1,302,000	1,087,000	977,000
Total Current Liabilities	45,167,000	22,807,000	15,032,000	11,576,000
Long Term Debt	4,330,000	6,015,000	7,145,000	7,211,000
Total Liabilities	155,379,000	28,822,000	22,177,000	18,787,000
Shareholders Equity
Retained Earnings	-653,170,000	-469,726,000	-343,082,000	-250,175,000
Total Shareholders Equity	95,391,000	206,582,000	161,025,000	185,093,000

Balance sheet annual history for KalVista Pharmaceuticals Inc (KALV).
Balance Sheet (Annual)	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30
Assets
Cash and Cash Equivalents	98,644,000	31,789,000	56,238,000	30,732,000	50,592,000
Short Term Investments	89,002,000	178,612,000	93,137,000	135,470,000	198,337,000
Net Receivables	15,141,000	10,871,000	16,568,000	14,098,000	10,418,000
Inventory	0	0	0	2,709,000	0
Total Current Assets	241,690,000	225,690,000	172,326,000	193,647,000	264,264,000
Property Plant Equipment	1,988,000	9,147,000	10,770,000	10,040,000	7,549,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	250,770,000	235,404,000	183,202,000	203,880,000	272,013,000
Liabilities
Account Payables	4,883,000	9,107,000	4,817,000	3,638,000	1,981,000
Short Term Debt	1,977,000	1,302,000	1,087,000	977,000	863,000
Total Current Liabilities	45,167,000	22,807,000	15,032,000	11,576,000	9,774,000
Long Term Debt	4,330,000	6,015,000	7,145,000	7,211,000	5,046,000
Total Liabilities	155,379,000	28,822,000	22,177,000	18,787,000	14,820,000
Shareholders Equity
Retained Earnings	-653,170,000	-469,726,000	-343,082,000	-250,175,000	-167,836,000
Total Shareholders Equity	95,391,000	206,582,000	161,025,000	185,093,000	257,193,000

Cash flow quarterly history for KalVista Pharmaceuticals Inc (KALV).
Cash Flow Statement (Quarterly)	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Operating Activities
Net Income	-183,444,000	-126,644,000	-92,907,000	-82,339,000
Depreciation & Amortization	941,000	816,000	718,000	564,000
Stock Based Compensation	12,291,000	21,915,000	9,922,000	11,086,000
Change in Working Capital	15,035,000	15,167,000	7,413,000	-12,322,000
Operating Cash Flow	-152,907,000	-89,231,000	-75,261,000	-78,134,000
Investing Activities
Capital Expenditure	-434,000	-443,000	-1,196,000	-931,000
Investments	-929,000	0	-1,196,000	-931,000
Investing Cash Flow	91,024,000	-84,719,000	41,415,000	57,860,000
Financing Activities
Debt Repayment	98,040,000	0	0	0
Common Stock Issued/Repurchased	61,687,000	96,945,000	56,582,000	1,581,000
Dividends Paid	0	0	0	0
Financing Cash Flow	159,727,000	150,714,000	58,116,000	1,581,000
Summary
Free Cash Flow	-153,341,000	-89,674,000	-76,457,000	-79,065,000
Net Change in Cash	99,826,000	-24,449,000	25,506,000	-19,860,000

Cash flow annual history for KalVista Pharmaceuticals Inc (KALV).
Cash Flow Statement (Annual)	2025-04-30	2024-04-30	2023-04-30	2022-04-30	2021-04-30
Operating Activities
Net Income	-183,444,000	-126,644,000	-92,907,000	-82,339,000	-46,244,000
Depreciation & Amortization	941,000	816,000	718,000	564,000	537,000
Stock Based Compensation	12,291,000	21,915,000	9,922,000	11,086,000	7,118,000
Change in Working Capital	15,035,000	15,167,000	7,413,000	-12,322,000	8,346,000
Operating Cash Flow	-152,907,000	-89,231,000	-75,261,000	-78,134,000	-30,171,000
Investing Activities
Capital Expenditure	-434,000	-443,000	-1,196,000	-931,000	-82,000
Investments	-929,000	0	-1,196,000	-931,000	-82,000
Investing Cash Flow	91,024,000	-84,719,000	41,415,000	57,860,000	-147,654,000
Financing Activities
Debt Repayment	98,040,000	0	0	0	0
Common Stock Issued/Repurchased	61,687,000	96,945,000	56,582,000	1,581,000	210,582,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	159,727,000	150,714,000	58,116,000	1,581,000	212,117,000
Summary
Free Cash Flow	-153,341,000	-89,674,000	-76,457,000	-79,065,000	-30,253,000
Net Change in Cash	99,826,000	-24,449,000	25,506,000	-19,860,000	34,803,000